WHO ICTRP trial
Eradication of Helicobacter pylori increases ghrelin production in the gastric…
ISRCTN59881192 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN59881192 |
|---|---|
| Public title | Eradication of Helicobacter pylori increases ghrelin production in the gastric mucosa |
| Primary sponsor | Inje University, Ilsan Paik Hospital (Korea, South) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | Korea, South |
| Conditions | Helicobacter pylori infection Infections and Infestations Helicobacter pylori infection |
| Interventions | The treatment group received a triple H. pylori eradication regimen consisting of 20 mg esomeprazole, 1,000 mg amoxicillin and 500 mg clarithromycin, twice daily for 7 days. The control group received no medication. |
| Registration date | Oct 3, 2008 |
| Target size | 30 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: